Download a Free White Paper
This week's Fierce Biotech is brought to you by TD2. Trouble viewing? Click here. |
Preclinical A Powerful Form of Immunotherapy |
| |
Emerging as one of the most innovative and promising cancer treatments today, CAR T-cell therapy has proved to provide clinicial benefit in multiple types of cancer. However, it doesn't come without risks and there are challenges to be considered when it comes to understanding the power of this therapeutic advancement and how to leverage it. |
| | |
| Guidelines for Organizations Looking to Explore CAR T-Cell Therapy Before embarking on the develppment of a new CAR T-cell therapy, keep in mind that although this treatment could provide significant benefit to patients, it is a complex and expensive therapy. Consider the following when planning your preclinical development path: Identify the type of cancer model you plan to treat and ensure growth in an in vivo setting Prepare your CAR T-cell therapy for administration Understand study duration and treatment persistence |
| | |
|
Free White Paper: CAR T-Cell Therapy: Revolutionizing Cancer Treatment Over a decade in the making, CAR T-cell therapy has proven to be one of the most innovative and promising treatments in oncology. Learn more about what companies should consider when it comes to this cutting edge treatment from our free white paper.
| |
|
|
| Contact Us Ready to get started? If you're seeking a partner who can help set your oncology drug program up for success from the onset, we can help. "TD2 has been an extremely valuable and flexible partner for CRISPR Therapeutics, performing many CAR T-cell mouse studies across multiple antigen targets in a number of oncology indications," says Dr. Jon Terrett, Head of Immuno-Oncology Research and Translation at CRISPR Therapeutics. We specialize in oncology-it's all we do-and our expert team aims to save you time, money and resources. Contact us to get started today. |
| | |
Unmatched Scientific Expertise | Accelerated Development | Committed to Your Goals | Patient-Centered |
| |
Want to reach 137,000+ Fierce Biotech subscribers with your own message? Contact aalcover@questex.com or call 202-824-5074.
You are currently subscribed as newsletter@newslettercollector.com. If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe. Refer to our Privacy Policy. Questex, LLC 685 3rd Avenue, 21st Floor New York, NY 10017 |